ArticleFrontiers in oncology2026
Case Report: The clear cell variant of papillary thyroid carcinoma: a clinicopathologic study of four cases with emphasis on
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clear cell variant of papillary thyroid carcinoma (CLCVPTC) is an exceedingly rare and diagnostically challenging subtype of papillary thyroid carcinoma (PTC), defined by distinctive histomorphologic features. Here, we aimed to delineate the clinicopathologic, immunohistochemical, and molecular genetic characteristics of CLCVPTC by retrospectively analyzing four pathologically confirmed cases diagnosed at our institution between 2018 and 2025, together with a comprehensive review of the published literature. The male to female ratio of the four CLCVPTC cases is 1: 3, with a median age of 60 years (range 45-68) and presented clinically with thyroid nodules. Histopathological evaluation demonstrated infiltrative tumor growth patterns with solid, trabecular, and focal papillary architectures. Tumor cells displayed abundant clear cytoplasm (more than 90% of all tumor cells in our cases, meeting the diagnostic threshold of >50%) and classic nuclear features of PTC, including ground-glass nuclei, nuclear grooves, and intranuclear inclusions. Lymph node metastases were observed in three cases. Immunohistochemical profiling revealed consistent positivity for TTF-1, Pax8, CK7, thyroglobulin (TG) and Galectin-3, and absence of expression for TPO, BRAF V600E mutation, and various neuroendocrine markers. Polymerase chain reaction (PCR) identified an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.